ONXX Onyx Pharmaceuticals, Inc. (MM)

Onyx Pharmaceuticals to Webcast June 15 Analyst Briefing RICHMOND, Calif., June 9 /PRNewswire-FirstCall/ -- Onyx Pharmaceuticals, Inc. (NASDAQ:ONXX) today announced today that it will webcast a post-ASCO analyst briefing on Tuesday, June 15, 2004, beginning at 4:30 p.m. Eastern Time. Clinical investigators: -- Bernard J. Escudier, M.D. of the Institut Gustave Roussy, France, -- Keith T. Flaherty, M.D. of the University of Pennsylvania in Philadelphia, and -- Mark J. Ratain, M.D. of the University of Chicago, will review recently reported clinical data for BAY 43-9006, being developed in collaboration with Bayer Pharmaceuticals Corporation. Interested parties may access a live webcast of the presentation by clicking on the link below: http://invite.mshow.com/findshow.aspx?usertype=0&cobrand=100&shownumber=168242 If for some reason you have a problem with the link above, you may Go to http://www.mshow.com/, Click on your global region, Enter Show Number 168242, Enter your email address, and Click on "Continue" to join the Webcast. It is recommended that listeners log on 15 minutes early in order to register and download any necessary software. If you are unable to participate during the live webcast, a recorded replay of the presentation will be available within 48 hours of the completion of the presentation through July 15. Onyx Pharmaceuticals is engaged in the development of novel cancer therapies that target the molecular basis of cancer. With its collaborators, the company is developing small molecule drugs, including BAY 43-9006 with Bayer Pharmaceuticals Corporation. For more information about Onyx's pipeline and activities, visit the company's website at http://www.onyx-pharm.com/. DATASOURCE: Onyx Pharmaceuticals, Inc. CONTACT: Julie Wood of Onyx Pharmaceuticals, Inc., +1-510-262-8757 Web site: http://www.onyx-pharm.com/

Copyright